Jacobs Levy Equity Management
APLS

Jacobs Levy Equity Management’s Apellis Pharmaceuticals APLS Stock Holding History

Jacobs Levy Equity Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-61,681
Closed -$2.48M – 946
2026
Q1 		$2.48M Buy
+61,681
New +$1.33M 0.01% 543
2024
Q2 		– Sell
-20,057
Closed -$1.18M – 956
2024
Q1 		$1.18M Buy
20,057
+903
+5% +$57.6K 0.01% 689
2023
Q4 		$1.15M Sell
19,154
-90,354
-83% -$4.58M 0.01% 693
2023
Q3 		$4.17M Buy
+109,508
New +$4.81M 0.02% 411
2022
Q1 		– Sell
-310,594
Closed -$14.7M – 995
2021
Q4 		$14.7M Sell
310,594
-203,047
-40% -$7.99M 0.1% 237
2021
Q3 		$16.9M Buy
513,641
+390,616
+318% +$21.9M 0.11% 211
2021
Q2 		$7.78M Sell
123,025
-138,243
-53% -$7.13M 0.05% 346
2021
Q1 		$11.2M Buy
261,268
+180,887
+225% +$8.56M 0.09% 269
2020
Q4 		$4.6M Sell
80,381
-39,862
-33% -$1.69M 0.04% 410
2020
Q3 		$3.63M Buy
120,243
+40,731
+51% +$1.22M 0.04% 413
2020
Q2 		$2.6M Buy
+79,512
New +$2.55M 0.03% 471

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Jacobs Levy Equity Management's APLS Position: Q2 2026 in Review

Jacobs Levy Equity Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 61,681 shares — an estimated $2.48M sold.

Jacobs Levy Equity Management first reported a position in APLS in Q2 2020 and held it in 11 quarters. The position peaked at $16.9M in Q3 2021. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Jacobs Levy Equity Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 61,681 Apellis Pharmaceuticals shares in Q2 2026, an estimated $2.48M.
  • Jacobs Levy Equity Management first reported a position in Apellis Pharmaceuticals in Q2 2020 and held it in 11 quarters.
  • Jacobs Levy Equity Management's Apellis Pharmaceuticals position peaked at $16.9M in Q3 2021.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.